Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C

[摘要] Combination therapy with pegylated interferon, ribavirin and a first-generation NS3/4A protease inhibitor, telaprevir or boceprevir, is the new strategy for treatment of genotype 1 chronic hepatitis C virus infection. This combination improves therapeutic efficacy but it also increases the risk of adverse events.

[学科分类] 皮肤病学

[关键词] boceprevir;interferon;itch;liver;peginterferon;skin;telaprevir;viral infection